Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. We apply our deep understanding of immunology to identify and create innovative drug ...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001193125-26-104547 | EDGAR | 74K words |
| 2025-03-14 | 2024-12-31 | 0000950170-25-039389 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0000950170-24-026249 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000906709-23-000004 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000906709-22-000005 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0000906709-21-000005 | EDGAR | — |
| 2020-02-28 | 2019-12-31 | 0000906709-20-000004 | EDGAR | — |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005639 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001564590-18-004105 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001564590-17-003064 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001193125-25-270230 | EDGAR | 45K words |
| 2025-08-08 | 2025-06-30 | 0000950170-25-105275 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067279 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0000950170-24-123570 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094231 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0000950170-24-057312 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-060475 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000906709-23-000012 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000906709-23-000008 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0000906709-22-000019 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0000906709-22-000014 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0000906709-22-000010 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001213900-26-027026 | EDGAR | 4K words |
| 2026-02-13 | 0001193125-26-049378 | EDGAR | — |
| 2026-02-10 | 0001193125-26-044751 | EDGAR | — |
| 2026-02-10 | 0001193125-26-043755 | EDGAR | — |
| 2026-01-27 | 0001213900-26-008210 | EDGAR | — |
| 2025-12-16 | 0001193125-25-320009 | EDGAR | — |
| 2025-11-21 | 0001213900-25-113606 | EDGAR | — |
| 2025-11-10 | 0001213900-25-107821 | EDGAR | — |
| 2025-11-06 | 0001213900-25-107180 | EDGAR | — |
| 2025-09-18 | 0001213900-25-088792 | EDGAR | — |
231 total filings indexed. 199 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000906709 |
| Ticker | NKTR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nektar.com |
| Listed | 1994-05-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report